Dr. Patel on Induction Therapy With Bendamustine and Rituximab in MCL

Video

Krish Patel, MD, oncologist, Swedish Cancer Institute, discusses induction therapy with bendamustine and rituximab (Rituxan; BR) in the treatment of patients with mantle cell lymphoma (MCL).

Krish Patel, MD, oncologist, Swedish Cancer Institute, discusses induction therapy with bendamustine and rituximab (Rituxan; BR) in the treatment of patients with mantle cell lymphoma (MCL).

At the 2018 ASH Annual Meeting, an abstract was presented on induction therapy with BR. Investigators assessed response rates, progression-free survival, and overall survival. Data were pulled from two phase II studies as well as from patients who had been treated off trial. BR was given for a total of 3 cycles, and if patients achieved a clinical response, they went on to receive 3 cycles of rituximab and cytarabine. This was followed by an autologous stem cell transplant.

This is an important study, states Patel, as the optimal induction regimen for newly diagnosed patients is unknown. Though there are many potential induction regimens from which to choose, the study provides compelling evidence that the combination of these agents is something to pursue in future trials.

Related Videos
Janice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences
Sekar Kethiresan, MD, on Following up VERVE-101 With Next-Generation Editing Therapies
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
© 2024 MJH Life Sciences

All rights reserved.